Albumin Human

Summary

Albumin Human (CHEMBL1201451) is an approved protein (ATC B05AA01); indicated across 48 conditions including lung disorder and nephrosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B05AA01
• Indications: 48 conditions
• Clinical trials: 190

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201451
Name	Albumin Human
Type	Protein
Max phase	4
ATC	B05AA01

Also known as: Albumin, Albumin (bovine), Albumin (human), Albumin bovine, Albumin human, Albumin human component of abi-009, Albumin human. plasma-derived, Albumin microspheres, human, Albumin test, blood, bovine

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

48 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lung disorder	4	MONDO:0005275	EFO:0003818
nephrosis	4	MONDO:0002331	MONDO:0002331
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
habitual spontaneous abortion	3	MONDO:0006774	EFO:1000954
chronic inflammatory demyelinating polyradiculoneuropathy	3	MONDO:0006702	EFO:1000868
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
toxic shock syndrome	3	MONDO:0001881	EFO:0006834
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
malignant pancreatic neoplasm	3	MONDO:0009831	EFO:1000359
postural orthostatic tachycardia syndrome	3	MONDO:0011479	EFO:1000645
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
oral cavity squamous cell carcinoma	3	MONDO:0004958	EFO:0000199
gastric adenocarcinoma	3	MONDO:0005036	EFO:0000503
paraganglioma	3	MONDO:0000448	EFO:1000453
breast neoplasm	3	MONDO:0021100	MONDO:0007254
endometrium neoplasm	3	MONDO:0021251	MONDO:0011962
systemic sclerosis	2	MONDO:0005100	EFO:0000717
intracerebral hemorrhage	2	MONDO:0013792	EFO:0005669
pneumonia	2	MONDO:0005249	EFO:0003106
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
macular degeneration	2	MONDO:0003004	EFO:0009606
kidney disorder	2	MONDO:0005240	EFO:0003086
cerebral infarction	2	MONDO:0002679	MONDO:0002679
graft versus host disease	2	MONDO:0013730	MONDO:0013730
alpha 1-antitrypsin deficiency	2	MONDO:0013282	Orphanet:60
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
adrenoleukodystrophy	2	MONDO:0018544	MONDO:0015339
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
burn	2	MONDO:0043519	EFO:0009516
adenocarcinoma	2	MONDO:0004970	MONDO:0003219
subarachnoid hemorrhage	1	MONDO:0005099	EFO:0000713
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
neoplasm	1	MONDO:0005070	EFO:0000616
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
systolic heart failure	1	MONDO:0006993	EFO:1001207
soft tissue sarcoma	1	MONDO:0018078	EFO:1001968

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 190.

Phase distribution

Phase	Trials
Not specified	54
PHASE2	42
PHASE3	33
PHASE4	32
PHASE1	11
PHASE2/PHASE3	9
PHASE1/PHASE2	8
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05463471	PHASE4	NOT_YET_RECRUITING	Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients
NCT05726136	PHASE4	RECRUITING	Fluid Challenge and Plasma Volume, During Surgery
NCT06535945	PHASE4	RECRUITING	Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation
NCT06667999	PHASE4	RECRUITING	The Intensive Care Platform Trial
NCT00108355	PHASE4	COMPLETED	Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
NCT00327704	PHASE4	COMPLETED	Early Albumin Resuscitation During Septic Shock
NCT00570960	PHASE4	TERMINATED	Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis
NCT00708747	PHASE4	COMPLETED	Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients
NCT00839358	PHASE4	COMPLETED	Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation
NCT00886925	PHASE4	COMPLETED	Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
NCT00936247	PHASE4	TERMINATED	Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)
NCT00968695	PHASE4	COMPLETED	Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
NCT01418521	PHASE4	UNKNOWN	Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery
NCT01530711	PHASE4	UNKNOWN	Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
NCT01553617	PHASE4	COMPLETED	VolulyteTM in Cardiac Surgery
NCT01559519	PHASE4	COMPLETED	Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
NCT01689506	PHASE4	TERMINATED	Fluid Resuscitation in Patients Suffering From Burns Injury
NCT01822600	PHASE4	COMPLETED	The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia
NCT02034279	PHASE4	TERMINATED	The INFECIR-2 Albumin Prevention Study
NCT02401490	PHASE4	UNKNOWN	Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
NCT02556580	PHASE4	UNKNOWN	Volume Kinetics for 20% Albumin in Different Clinical Situations
NCT02560519	PHASE4	COMPLETED	Albumin in Cardiac Surgery
NCT02738190	PHASE4	COMPLETED	Albumin vs. Plasma for PEdiAtric pRiming Trial
NCT02899702	PHASE4	WITHDRAWN	Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
NCT03153306	PHASE4	UNKNOWN	Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient
NCT03167645	PHASE4	COMPLETED	SUbstition of PERioperative Albumin Deficiency Disorders
NCT03202524	PHASE4	WITHDRAWN	Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
NCT03373318	PHASE4	UNKNOWN	Influence of Albumin on Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation
NCT03453320	PHASE4	COMPLETED	Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects
NCT03848507	PHASE4	COMPLETED	Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
NCT04058236	PHASE4	UNKNOWN	Glycocalyx Levels in Patients Undergoing Pancreatectomy
NCT04216784	PHASE4	TERMINATED	Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients
NCT05056220	PHASE3	RECRUITING	Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
NCT05125055	PHASE2/PHASE3	RECRUITING	Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05610332	PHASE3	NOT_YET_RECRUITING	Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
NCT06630923	PHASE3	RECRUITING	PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS
NCT06704620	PHASE3	NOT_YET_RECRUITING	Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
NCT07139392	PHASE3	NOT_YET_RECRUITING	A Clinical Comparison of Connective Tissue Graft and Alb-PRF for Rebuilding Interdental Papilla
NCT07212582	PHASE3	NOT_YET_RECRUITING	Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)
NCT07263308	PHASE3	RECRUITING	Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).